Comparison
NMN vs. Nicotinamide Riboside (NR)
NMN or NR – which NAD+ precursor is better supported?
4 min read updated October 6, 2026
In the BK-Score: NMN Thin human evidence (human evidence 5 out of 10, safety data 5 out of 10), Nicotinamide riboside Supported, with caveats (human evidence 6 out of 10, safety data 6 out of 10).
The short answer
Neither has shown a clinical benefit in humans. Both reliably raise NAD+ levels in the blood – that is a surrogate marker, not an outcome. There are more placebo-controlled studies on nicotinamide riboside, and a critical review in Science Advances 2023 concludes that most clinical endpoints remained unaffected; for inflammatory markers there are indications, but no consistent finding. Its status is in motion: the US FDA removed NMN from the dietary supplement category in 2022 but reversed that decision in September 2025, so NMN is again permitted as a supplement in the US. In the EU, EFSA assessed beta-NMN as safe up to 300 mg per day in 2026; authorization by the European Commission is still pending. If you choose between the two, you are choosing between two substances whose benefit is an open question.
The numbers side by side
| Axis | NMN | Nicotinamide riboside (NR) | Difference |
|---|---|---|---|
| Human evidenceHow much data from humans there is, and how good it is | 5 | 6 | Nicotinamide riboside better studied |
| MechanismHow well the chain of action is understood | 6 | 6 | even |
| Safety dataHow well safety has been studied – not how safe it is | 5 | 6 | Nicotinamide riboside better studied |
| Hype gap10 means: the marketing stays in line with the data | 2 | 3 | Nicotinamide riboside closer to the data |
| Track record of useHow much documented use in humans there is – does not measure whether it works | 5 | 5 | even |
| Assessment | Thin human evidence · Supported, with caveats | ||
“Track record of use” measures how long and how widely something has been used in humans – not whether it works. The BK-Score is a subjective assessment by Biohacking Kompakt based on published scoring rules. It is not a scientific rating, not the consensus of a medical society and not a medical recommendation.
Why these numbers
NMN
In humans there are now 15 small randomized trials lasting 2 to 24 weeks; one meta-analysis (Yang 2026) finds no effects on weight, blood glucose, blood lipids or blood pressure, another none on muscle function. Endpoint data are lacking; the NAD pathway is plausible, but the increase in tissue is weakly supported. Safety data are short-term only – and hardly any longevity product is more overhyped.
Nicotinamide riboside (NR)
An unusually high number of RCTs for a longevity supplement – with a clear pattern: the NAD+ level in the blood rises reliably and in a dose-dependent manner (plus 22, 51 and 142 percent; Conze 2019), also in the brain (NADPARK 2022). A critical review of 25 human studies (Science Advances 2023) finds few clinically relevant effects and a tendency to overstate findings; insulin sensitivity (clamp, 40 men, 12 weeks; Dollerup 2018), glucose, body composition and blood pressure mostly remained unaffected, and the blood pressure effect of an early study was not confirmed. For inflammation there are indications (NADPARK), but no consistent finding (Remie 2020 with no effect on inflammatory markers). For aging itself, no endpoint data exist in humans; the phase III study NOPARK with 410 Parkinson's patients has been completed since June 17, 2025, but is unpublished. Safety has been properly studied over weeks to months, including with 3,000 mg over 4 weeks (NR-SAFE 2023); EFSA assessed up to 300 mg per day as safe (2019).
Frequently asked questions
Do NMN and NR really raise NAD+ levels?
Yes, that is the best-supported part. Several placebo-controlled studies show a measurable rise in NAD+ levels in the blood. What remains open is whether a health benefit follows from this – clinical endpoints such as insulin sensitivity, blood pressure and body composition remained largely unchanged in the studies.
Is NMN allowed as a dietary supplement?
In the US, yes again: the FDA excluded NMN in 2022 because it was being tested as a drug candidate, and withdrew that position in September 2025. In the EU, NMN is not yet authorized as a novel food; EFSA assessed beta-NMN as safe up to 300 mg per day in 2026, and the European Commission has not yet decided.
What would proof of benefit require?
A randomized trial with a hard endpoint – mortality, disease incidence, functional capacity – over years rather than weeks. Such studies do not exist for either substance.
See all ratings in the ranking
Information only, not medical advice and no usage or dosage recommendation. Prescription and unapproved drugs belong in the hands of a physician.